JP2023500318A5 - - Google Patents

Info

Publication number
JP2023500318A5
JP2023500318A5 JP2022525641A JP2022525641A JP2023500318A5 JP 2023500318 A5 JP2023500318 A5 JP 2023500318A5 JP 2022525641 A JP2022525641 A JP 2022525641A JP 2022525641 A JP2022525641 A JP 2022525641A JP 2023500318 A5 JP2023500318 A5 JP 2023500318A5
Authority
JP
Japan
Prior art keywords
chromatography column
housing assembly
chromatography
internal cavity
stationary phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500318A (ja
JP7746263B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/080476 external-priority patent/WO2021084050A1/en
Publication of JP2023500318A publication Critical patent/JP2023500318A/ja
Publication of JP2023500318A5 publication Critical patent/JP2023500318A5/ja
Application granted granted Critical
Publication of JP7746263B2 publication Critical patent/JP7746263B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525641A 2019-10-30 2020-10-29 細胞選択および/または細胞刺激デバイスならびに使用方法 Active JP7746263B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928303P 2019-10-30 2019-10-30
US62/928,303 2019-10-30
PCT/EP2020/080476 WO2021084050A1 (en) 2019-10-30 2020-10-29 Cell selection and/or stimulation devices and methods of use

Publications (3)

Publication Number Publication Date
JP2023500318A JP2023500318A (ja) 2023-01-05
JP2023500318A5 true JP2023500318A5 (cg-RX-API-DMAC7.html) 2023-11-02
JP7746263B2 JP7746263B2 (ja) 2025-09-30

Family

ID=73172649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525641A Active JP7746263B2 (ja) 2019-10-30 2020-10-29 細胞選択および/または細胞刺激デバイスならびに使用方法

Country Status (11)

Country Link
US (1) US20250237628A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051402B1 (cg-RX-API-DMAC7.html)
JP (1) JP7746263B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220101641A (cg-RX-API-DMAC7.html)
CN (1) CN114929360A (cg-RX-API-DMAC7.html)
AU (1) AU2020377043B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022008023A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159380A1 (cg-RX-API-DMAC7.html)
IL (1) IL292319B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005145A (cg-RX-API-DMAC7.html)
WO (1) WO2021084050A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
JP7738826B2 (ja) * 2021-10-29 2025-09-16 東ソー株式会社 遺伝子改変t細胞の製造方法
EP4223381B1 (en) * 2022-02-02 2025-04-02 Sartorius BIA Separations d.o.o. Method of purifying or removing a target component from full plasma
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
US20260232729A1 (en) 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IN165717B (cg-RX-API-DMAC7.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE3729002A1 (de) * 1987-08-31 1989-04-20 Merck Patent Gmbh Chromatographiesaeulen-kartuschensystem
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
CA2164226C (en) 1993-06-04 2011-02-08 Carl H. June Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
WO1996024606A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
CA2283716A1 (en) 1997-03-14 1998-09-17 Gabriel O. Reznik Multiflavor streptavidin
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO1999061065A1 (en) 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2224726T3 (es) 1998-12-24 2005-03-01 Biosafe S.A. Sistema de separacion sanguinea indicado en particular para la concentracion de celulas madre hematopoyeticas.
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
GB2435760B (en) * 2004-10-07 2010-07-14 Waters Investments Ltd HPLC Capillary Column Cartridge Cassette
EP1812465B1 (en) 2004-11-12 2016-09-07 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US20080171951A1 (en) 2005-03-23 2008-07-17 Claude Fell Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine
US20100005867A1 (en) * 2006-07-17 2010-01-14 Agilent Technologies, Inc. Temperature adjustment of a fluidic sample within a fluidic device
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
US11185795B2 (en) * 2012-07-06 2021-11-30 Waters Technologies Corporation Techniques for thermally insulating a chromatographic column
US10413846B2 (en) * 2012-07-06 2019-09-17 Waters Technologies Corporation Techniques for thermally insulating a liquid chromatographic column
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
US10220332B2 (en) * 2013-02-15 2019-03-05 Douglas T. Gjerde Columns for isolation, detection and use of biological cells
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
RS62471B1 (sr) 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
AU2015357535B2 (en) 2014-12-05 2020-05-14 Eureka Therapeutics, Inc. Antibodies targeting G-protein coupled receptor and methods of use
DK3227339T3 (da) 2014-12-05 2022-01-10 Memorial Sloan Kettering Cancer Center Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
US20180325964A1 (en) * 2015-11-20 2018-11-15 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
WO2017180969A2 (en) * 2016-04-15 2017-10-19 Waters Technologies Corporation Techniques for thermally insulating a chromatographic column
MA45784A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US20210393691A1 (en) 2018-11-06 2021-12-23 Juno Therapeutics, Inc. Process for producing genetically engineered t cells

Similar Documents

Publication Publication Date Title
US20230295567A1 (en) Methods for culturing cells and kits and apparatus for same
US20210269502A1 (en) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
JP2022512872A5 (cg-RX-API-DMAC7.html)
US20200093861A1 (en) Antigen binding receptor formats
CN106699888B (zh) 一种pd-1抗体及其制备方法和应用
KR20200019126A (ko) 올리고머 입자 시약 및 이의 사용 방법
JP2021534829A5 (cg-RX-API-DMAC7.html)
JP2023519107A5 (cg-RX-API-DMAC7.html)
AU2016341533A1 (en) Methods for culturing cells and kits and apparatus for same
CA3159380A1 (en) Cell selection and/or stimulation devices and methods of use
CA3117720A1 (en) Process for producing genetically engineered t cells
CN104829726A (zh) 一种双特异性抗体cd19xcd3的构建及应用
JP2023519106A5 (cg-RX-API-DMAC7.html)
WO2019178518A1 (en) Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
CN112004825A (zh) 细胞周期蛋白a1特异性t细胞受体及其用途
CN104829727A (zh) 一种双特异性抗体cd19×cd3的构建及应用
CN120092090A (zh) 工程化嵌合抗原受体免疫细胞及其应用
JP6842688B2 (ja) キメラ抗原受容体
CN117795082A (zh) 抗EGFRviii抗体、多肽、表达前述多肽的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述多肽的碱基序列的多核苷酸或载体
Pekar Novel technologies for antibody hit discovery and engineering of antibody-like proteins with therapeutic relevance
CN121773331A (zh) 对肿瘤性滤泡调节性t细胞及肿瘤性滤泡杀伤性t细胞进行定量的方法、对肿瘤性滤泡调节性t细胞及肿瘤性滤泡杀伤性t细胞进行筛选的方法、治疗用组合物及试剂盒
WO2024254772A1 (zh) 工程化的滋养细胞及其用途
TH2301005422A (th) ตัวรับแอนติเจนลูกผสมที่จับจำเพาะต่อโปรตีนบี-เซลล์เมทูเรชันแอนติเจน (bcma) และกรรมวิธีการผลิตที-เซลล์ที่มีตัวรับแอนติเจนแบบลูกผสมดังกล่าว
CN116554328A (zh) 一种靶向trbv12的单链抗体、car、car-nk细胞及应用
Jones et al. Research reports Extension of the four-parameter logistic model for ELISA to multianalyte analysis